
Youth Vaping Rates Plummet: Canadian Vaping Association Urges Shift to Adult Harm Reduction Strategies
Ottawa, ON, May 21, 2025 (GLOBE NEWSWIRE) — Statistics Canada's latest findings from the 2025 Canadian Health Survey on Children and Youth reveal a dramatic decline in youth vaping, with past 30-day use among Canadians aged 12–17 dropping to 7.2%, a near 50% reduction from the peak rate of 13.2% recorded in 2019.
Misleading Comparisons Undermine Evidence-Based Debate on Vaping
Despite this clear progress, certain anti-vaping organizations continue to misrepresent data, inflating perceptions of youth vaping prevalence to justify restrictive policies that overlook the needs of adult consumers.
In December 2024, Health Canada published the first Canadian Substance Use Survey (CSUS) 2023, which included a redesigned sampling methodology aimed at improving representation of respondents aged 15–24. Most importantly, the survey's Technical Notes explicitly caution against comparing the CSUS 2023 results to prior studies, including the Canadian Tobacco and Drug Survey (2013–2017) and the Canadian Tobacco and Nicotine Survey (2019–2022), due to the fundamental methodological changes.
Despite this clear disclaimer, several prominent anti-vaping organizations erroneously compared the data regardless of the warnings, claiming 'a third of teenagers vape' as a justification to fast-track flavour restrictions. By blurring the line between adult and youth use and disregarding Health Canada's guidance, these groups distort public understanding, stifle meaningful health dialogues, and risk driving reactionary, unsound policy decisions.
'Misleading claims about youth vaping rates distract from the real public health opportunity: supporting adult smokers seeking less harmful alternatives,' said Sam Tam, President of the Canada Vaping Association. 'With youth use at historic lows, policymakers should now focus on harm reduction for the 4.6 million Canadian adults who smoke, the group that benefits the most from regulated, less harmful alternatives.'
The CVA emphasizes that vaping remains an important tool for those looking to get off cigarettes, restricting access or imposing excessive regulations on adult-focused products risks driving former smokers back to deadly tobacco use or unregulated products purchased from illicit markets.
'The data is clear: youth vaping has been declining since its peak in 2019. However, it remains a critical issue, and CVA remains committed to prevention and education efforts to sustain this downward trend. Now is the time to build on this progress by ensuring that Canadians have access to accurate information and safer alternatives,' added Sam Tam. 'We call on health leaders and policymakers to align strategies with the evidence: protect youth through continued education and stronger enforcement, while empowering adults to make informed choices and reducing the stigma around being a smoker.'
The decline in youth vaping coincides with the continued expansion of Canada's regulated age gated specialty vape retail industry, which enforces strict ID verification protocols and complies with federal and provincial regulations. These licensed retailers serve adults exclusively and represent one of the few consumer channels in Canada with mandatory age verification at both the point of sale and delivery.
Moving forward, policymakers must prioritize accurate, science-driven data when creating fair and effective regulations that protect youth without sacrificing progress for Canadians looking to stop smoking. Misguided policies rooted in outdated or misrepresented statistics risk undermining harm reduction efforts, pushing former smokers back to cigarettes or fueling unregulated, illicit markets. By aligning regulations with the latest evidence, and rejecting fear-based narratives, Canada can continue its position as a global leader in balanced, progressive public health strategy.
In the last year, there has been a lot of push for nationwide flavour bans as a means to end youth vaping. Prohibitive measures like this do little to stop youth from vaping and often backfire by pushing them further into the illicit market. When legal options are restricted, determined teens don't simply stop, they shift to unregulated sources where flavoured products are still widely available. These underground channels not only make it easier for youth to obtain vapes, but also expose them to untested, potentially more dangerous products. As history has shown with other forms of prohibition, restricting access doesn't eliminate demand, it just drives it into the shadows.
The CVA remains committed to collaborating with governments, ministries and stakeholders to safeguard youth while continuing to offer less-harmful alternatives for adult consumers.
By uniting evidence, innovation, and public health priorities, we can save lives, end preventable smoking-related deaths, and create a healthier Canada where harm reduction offers adults an escape from deadly tobacco addiction, once and for all.
Key Notes:
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Two Transplant Recipients Meet Their Lifesaving Donors at Gift of Life Marrow Registry Charitable Gala
Annual Event Supports Mission to Add New Donors to Registry and Celebrates 30th Transplant Anniversary of Gift of Life Founder & CEO Jay Feinberg Transplant recipient meets stem cell donor for first time Two-year-old boy introduced to lifesaving stem cell donor NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Gift of Life Marrow Registry hosted its One Huge Night NYC Gala, where two lifesaving blood stem cell donors were united with their transplant recipients, one only two years old, for the first time. The event, held at The Lighthouse at Chelsea Piers in New York, N.Y. on June 4, 2025, brought together donors, transplant recipients, business leaders, and community members in support of Gift of Life's mission to cure blood cancer, inherited immune disorders and other diseases. The gala also marked the 30th anniversary of Jay Feinberg's transplant, the Founder and CEO of Gift of Life Marrow Registry, whose personal journey as a recipient inspired the creation of the organization. The donor-recipient pairs were introduced by Montana Tucker, an award-winning performer and social media activist, and David Blumenfeld, Principal of the Blumenfeld Development Group. The first donor and recipient pair to be introduced included Boris Semkhayev, a 30-year-old medical student from New York City and his 26-year-old recipient, Michelle Bibichayev, from Flushing, Queens, N.Y. In June 2023, Bibichayev was diagnosed with Acute Myeloid Leukemia, initially mistaking her symptoms for pregnancy-related fatigue. After routine blood work, Bibichayev learned of her life-threatening condition and feared for both her own survival and her baby's future. Faced with the need for a stem cell transplant, she felt nervous, but hopeful. Even while enduring strenuous chemotherapy and recovering from an emergency C-section, she remained optimistic. 'Thank you to Boris and Gift of Life for giving me a second chance at life,' said Bibichayev. 'I had a rare type of cancer, and I didn't think I would survive or that my son would have a mother. You saved my life.' Semkhayev joined the Gift of Life registry while attending Hunter College in 2015. When he found out he was a match for a patient, he was about to begin a new semester in medical school but immediately agreed to help. 'If your brother or sister, God forbid, needed a life-saving transplant, chances are you or anyone in your family couldn't donate,' said Semkhayev. 'But by others in your community signing up, your loved one could receive that second chance. You can be that hero. My recipient was from my own ethnic community, and that connection made all the difference.' The second pair of the evening shared an equally touching story. Lindsay Wilson, a 24-year-old recent graduate from St. Petersburg, Fla., was deeply moved to meet Logan Rich-Aiken, her two-year-old recipient from Waldorf, Md., who was battling Inherited Immune Systems Disorders. She joined Gift of Life's registry in 2020 at a donor recruitment drive held at Florida State University. She was thrilled when she got the call four-and-a-half years later letting her know that she was a match for a little boy in need. 'Each day was a reminder that committing to help save a life is nothing compared to what the recipients and their families are enduring," said Wilson. "We have the power to make a difference, and that difference can start with joining the registry.' The gala served as a platform to recognize the unwavering commitment and outstanding advocacy of several supporters. The organization's highest honor, the Partners for Life Award, was presented to Lynn Schusterman for her support and generosity through the Charles and Lynn Schusterman Family Foundation. Her long-standing partnership and collaborative recruitment efforts have inspired young people to drive positive change in the world. In addition, longtime Gift of Life supporter, board of directors member and transplant recipient Dr. Stephen Colen received the Lifetime Achievement Award, and international law firm Fried Frank was honored with the Corporate Partner Award. Wendy and Stephen B. Siegel, Gift of Life of Life Board Member and Chairman of the Board, respectively, served as Gala Chairs, Susan and Edward Blumenfeld, Board Member, served as Honorary Gala Chairs and Heller and Jeffrey Goldberg, Board Member, served as Gala Vice Chairs. The event was emceed by Ezra Fineman, a 15-year-old stem cell transplant recipient from Fairlawn, N.J. About Gift of Life Marrow RegistryGift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating blood stem cell and bone marrow transplants for patients with leukemia, lymphoma, and other blood-related diseases. The registry houses its own state-of-the-art stem cell collection center, biobank, and laboratory. To learn more about Gift of Life Marrow Registry, visit Media contact: Amy GlanzmanPhone: (561) 982-2900; Email: aglanzman@ Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Medical Terminology Software Outlook 2029: Key Trends, Vendor Insights, and Global Opportunities
Key growth drivers in the medical terminology software market include minimizing medical errors and the rising demand for terminology software. The report covers market size, trends, vendor analysis, and geographical segmentation, providing insights on the evolving market landscape for healthcare providers, payers, and IT vendors. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Medical Terminology Software Market 2025-2029" has been added to offering. The medical terminology software market is poised for significant expansion, with projections indicating a growth of USD 3.80 billion from 2024 to 2029, at an impressive CAGR of 26.3%. This comprehensive report offers an in-depth analysis of market size and forecasts, emerging trends, growth drivers, and challenges, along with a detailed vendor analysis covering approximately 25 prominent vendors. The report presents a current market scenario, incorporating the latest insights on trends and drivers, and evaluates the overall market environment. The industry's growth is significantly driven by a heightened focus on reducing medical errors and a rising global demand for robust medical terminology software, fueled by discrepancies in terminology content worldwide. The analysis highlights the growing adoption of healthcare information technology as a significant growth area for the market. Additionally, the rise in medical tourism and increasing strategic alliances with new product launches are expected to create substantial market demand. The medical terminology software market segmentation includes: By End-user Healthcare providers Healthcare payers Healthcare IT vendors By Type Services Platforms By Application Data integration Data aggregation Reimbursement Clinical trials By Geographical Landscape North America Europe APAC South America Middle East and Africa Areas covered within the report: Medical Terminology Software Market sizing Medical Terminology Software Market forecast Medical Terminology Software Market industry analysis The report's robust vendor analysis is designed to help clients enhance their market position. Key players studied include: 3M Co. Apelon Inc. B2i Healthcare Pte Ltd. BITAC MAP SL BT Clinical Computing Clinical Architecture LLC Epic Systems Corp. Henry Schein Inc. HiveWorx Intelligent Medical Objects Inc. Medaara Healthcare Solutions Medocomp Systems Inc. Regenstrief Institute Rhapsody SNOMED International Spellex Corp. West Coast Informatics Wolters Kluwer NV Additionally, the report examines upcoming trends and challenges poised to influence market growth, offering strategic insights for leveraging future Topics Covered: Market Analysis Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Criticality of inputs and Factors of differentiation Factors of disruption Impact of drivers and challenges Market Landscape Market ecosystem Market characteristics Value chain analysis Market Sizing Market definition Market segment analysis Market size 2024 Market outlook: Forecast for 2024-2029 Historic Market Size Global Medical Terminology Software Market 2019 - 2023 End-user segment analysis 2019 - 2023 Type segment analysis 2019 - 2023 Application segment analysis 2019 - 2023 Geography segment analysis 2019 - 2023 Country segment analysis 2019 - 2023 Qualitative Analysis Impact of AI on Global Medical Terminology Software Market Five Forces Analysis Five forces summary Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition Market Segmentation by End-user Market segments Comparison by End-user Healthcare providers - Market size and forecast 2024-2029 Healthcare payers - Market size and forecast 2024-2029 Healthcare IT vendors - Market size and forecast 2024-2029 Market opportunity by End-user Market Segmentation by Type Market segments Comparison by Type Services - Market size and forecast 2024-2029 Platforms - Market size and forecast 2024-2029 Market opportunity by Type Market Segmentation by Application Market segments Comparison by Application Data integration - Market size and forecast 2024-2029 Data aggregation - Market size and forecast 2024-2029 Reimbursement - Market size and forecast 2024-2029 Clinical trials - Market size and forecast 2024-2029 Market opportunity by Application Customer Landscape Geographic Landscape Geographic segmentation Geographic comparison North America - Market size and forecast 2024-2029 Europe - Market size and forecast 2024-2029 APAC - Market size and forecast 2024-2029 South America - Market size and forecast 2024-2029 Middle East and Africa - Market size and forecast 2024-2029 Market opportunity By Geographical Landscape Drivers, Challenges, and Opportunity/Restraints Market drivers Market challenges Impact of drivers and challenges Market opportunities/restraints Competitive Landscape Competitive Landscape Landscape disruption Industry risks Competitive Analysis Companies profiled Company ranking index Market positioning of companies For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday June 5, 2025, at 10:30 am-11:00 am EDT (14:30-15:00 GMT / 16:30-17:00 CET). A live video webcast of the presentation will be available to the general public and can be accessed at After the event, a recording will be available for replay for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS Benedikt Stefansson, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data